Antibacterial 01
Engineered to outlast resistance.
LBX242 is structurally disruptive in a way that target pathogens cannot route around. No evolutionary resistance has been observed across two decades of study.
Pre-clinical pharmaceutical platform Est. 2023
An Integrated Pharmaceutical Antibacterial & Antiviral Platform
Stage: Pre-clinical
Advancing proprietary, dual-action mechanisms engineered to neutralize viral transmission and overcome antimicrobial resistance at the molecular source.
20+ yrs
No observed evolutionary resistance
2
Patented assets — botanical and synthetic
3
Expedited FDA pathways in play
WHO list
Multi-drug-resistant target pathogens
The opportunity
A resistance crisis that conventional antibiotics cannot answer.
Multi-drug-resistant pathogens outpace conventional antibiotics because every single-site drug eventually selects for resistance. The World Health Organization has named antimicrobial resistance among the foremost threats to global health.
Logix approaches the problem at the molecular source. A single patented composition confronts resistant bacteria in a structurally disruptive way that does not give evolution a foothold, while extending to viral transmission and tissue repair.
The platform
One patented composition. Three therapeutic fronts.
LBX242 is a patented class of structurally disruptive antimicrobials — a proprietary engine expressed across three modes of action. Not a pipeline of unrelated molecules: one composition, deployed three ways.
Antibacterial 
Antiviral 02
Active at the point of entry.
The same composition acts against enveloped respiratory viruses at the point of entry, interrupting transmission before infection takes hold.
Angiogenic 03
Supports tissue repair.
Beyond defense, the composition promotes angiogenesis and supports a regenerative tissue-repair pathway, addressing the conditions required for healing.
Inquire About LBX242 Mechanism of Action
Mechanism detail is shared under confidentiality.
Clinical & regulatory momentum
Two patented assets across parallel FDA pathways.
Two independently patented compositions — one botanical, one synthetic — multiply delivery options and de-risk capital across parallel pathways. Both express the same patented LBX242 composition.
Asset 01
Botanical matrixLBX242
- Composition
- A patented botanical matrix.
- Prior use
- Three decades of broad global human use of the natural composition from which LBX242 is derived.
- FDA pathway
- 505(b)(1) botanical pathway, qualifying on prior human use.
Asset 02
Synthetic small moleculeLBX242
- Composition
- Synthetic LBX242 derivative, engineered for precision delivery.
- Designation
- QIDP under the GAIN Act: +5 years exclusivity and Fast Track.
- FDA pathway
- 505(b)(2) with the LPAD pathway, scaling trial burden to a resistant population.
Validation
Built on institutional rigor.
Logix maintains a strategic agreement with Mayo Clinic, and is led by a team spanning clinical medicine, FDA regulatory strategy, quality systems, and intellectual-property law.
Strategic agreement
Mayo Clinic
Independent Medical Advisory Board
505(b)
(b)(1) & (b)(2) FDA pathways
QIDP
GAIN Act · LPAD designation
Gateway
For scientific, regulatory, and partnership inquiries.
Detailed materials — clinical data, the executive summary, and mechanism-of-action briefings — are provided to qualified parties on request.
- Phone
- +1 (800) 916-1220
- Office
- Monterey, California, United States